臨床泌尿器科76巻8号

2022年07月発行

特集 泌尿器腫瘍における放射線治療―変革期を迎えた令和のトレンド

〈腎細胞癌・膀胱癌〉

膀胱癌に対する膀胱温存療法の現状と課題

著者： 木村友和¹ 西山博之¹

所属機関： ¹筑波大学医学医療系腎泌尿器外科学分野

ページ範囲：P.588 - P.594

文献概要

▶ポイント

・膀胱温存療法は根治を目的として行う経尿道的膀胱腫瘍切除術（TURBT），化学療法，放射線療法によるTrimodal therapyである．

・膀胱温存療法のよい適応は，cT2-3N0M0，単発，尿路上皮癌の単一組織型，併存上皮癌（CIS）なし，水腎症なし，前立腺部尿道や頸部以外である．

・近年，免疫チェックポイント阻害薬を組み合わせた新たな膀胱温存療法が開発されており，今後の結果が待たれている．

参考文献

1） NCCN Guidelines Version 5.2020. Muscle Invasive Bladder Cancer （BL-5,BL-7）

2） Huddart RA, et al : Clinical and Patient-Reported Outcomes of SPARE ― A Randomised Feasibility Study of Selective Bladder Preservation versus Radical Cystectomy. BJU Int 120 : 639-650, 2017

3） Kimura T, et al : Bladder Preservation Therapy for Muscle Invasive Bladder Cancer : The Past, Present and Future. Jpn J Clin Oncol 50 : 1097-1107, 2020

4） Ploussard G, et al : Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-Invasive Bladder Cancer : A Systematic Review. Eur Urol 66 : 120-137 2014

5） Bruins HM, et al : The Effect of the Time Interval Between Diagnosis of Muscle-Invasive Bladder Cancer and Radical Cystectomy on Staging and Survival : A Netherlands Cancer Registry Analysis. Urol Oncol 34 : 166. e1-6, 2016

6） Sabaa MA, et al : Combined Modality Treatment with Bladder Preservation for Muscle Invasive Bladder Cancer. Urol Oncol 28 : 14-20, 2010

7） Rödel C, et al : Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer : Long-Term Results. J Clin Oncol 20 : 3061-3071, 2002

8） Japanese Society for Radiation Oncology : Radiation treatment planning guideline. Urology. Available via JASTRO HP （Japanese）　https://www. jastro.or.jp/medicalpersonnel/guideline/2016/06urinary.pdf （2022年6月1日閲覧）

9） Viswanathan AN, et al : Radiation Dose-Volume Effects of the Urinary Bladder. Int J Radiat Oncol Biol Phys 76 : S116-122, 2010

10） Emami B, et al : Tolerance of Normal Tissue to Therapeutic Irradiation. Int J Radiat Oncol Biol Phys 21 : 109-122, 1991

11） Thariat J, et al : Image-Guided Radiation Therapy for Muscle-Invasive Bladder Cancer. Nat Rev Urol 9 : 23-29, 2011

12） James ND, et al : Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer. N Engl J Med 366 : 1477-1488, 2012

13） Perdona S, et al : Bladder-Sparing, Combined Modality Approach for Muscle-Invasive Bladder Cancer : A Multiinstitutional, Long-Term Experience. Cancer 112 : 75-83, 2008

14） Mak RH, et al : Long-term Outcomes in Patients with Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy : A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32 : 3801-3809, 2014

15） Onozawa M, et al : Analysis of Intravesical Recurrence After Bladder-Preserving Therapy for Muscle-Invasive Bladder Cancer. Jpn J Clin Oncol 42 : 825-830, 2012

16） Wolf H, et al : Urothelial Dysplasia Concomitant with Bladder Tumours : A Determinant for Future New Occurrences in Patients Treated by Full-Course Radiotherapy. Lancet 1 : 1005-1008, 1985

17） Milosevic M, et al : Radiotherapy for Bladder Cancer. Urology 69 : 80-92, 2007

18） Gakis G, et al : ICUD-EAU International Consultation On Bladder Cancer 2012 : Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol 63 : 45-57, 2013

19） Nagumo Y, et al : A Single-Institute Experience of Trimodal Bladder-Preserving Therapy for Histologic Variants of Urothelial Carcinoma. Int J Clin Oncol 25 : 354-361, 2020

20） Shipley WU, et al : Selective Bladder Preservation by Combined Modality Protocol Treatment : Long-Term Outcomes of 190 Patients with Invasive Bladder Cancer. Urology 60 : 62-67, 2002

21） Tsai HK, et al : Association of Statin Use with Improved Local Control in Patients Treated with Selective Bladder Preservation for Muscle-Invasive Bladder Cancer. Urology 68 : 1188-1192, 2006

22） Hiniker SM, et al : A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy. Transl Oncol 5 : 404-407, 2012

23） Chen DS, et al : Molecular Pathways : Next-Generation Immunotherapy ― Inhibiting Programmed Death-Ligand 1 and Programmed Death-1. Clin Cancer Res 18 : 6580-6587, 2012

24） Sekino Y, et al : Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy for Invasive Bladder Cancer （BPT-ART） ― A Study Protocol for an Open-Label, Phase II, Multicenter Study. Contemp Clin Trials Commun 21 : 100724, 2021